Literature DB >> 3061002

Lipoprotein-mediated cellular mechanisms for atherogenesis in hypertriglyceridemia.

S H Gianturco1, W A Bradley.   

Abstract

Structurally and functionally abnormal VLDL exist in hypertriglyceridemic humans. These large abnormal VLDL, in contrast to large normal VLDL, interact with cell surface receptors. One large VLDL particle carries far more total cholesterol than one LDL particle. Receptor-mediated uptake of abnormal VLDL is injurious to endothelial cells and converts macrophages into foam cells in vitro. These observations lead to the hypothesis that if similar phenomena occur in vivo, abnormal VLDL, which have prolonged residence times and increased opportunity to interact with arterial cells, are atherogenic by promoting endothelial injury and initiating foam cell formation. Since premature atherosclerosis is associated with some forms of hypertriglyceridemia and foam cells accumulate in certain hypertriglyceridemic subjects, similar events may indeed occur in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3061002     DOI: 10.1055/s-2007-1002770

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  3 in total

1.  Atherosclerosis and Liver Function Tests in Coronary Angiography Patients.

Authors:  Y C Doganer; J E Rohrer; U Aydogan; D C Agerter; T Cayci; C Barcin
Journal:  West Indian Med J       Date:  2015-05-08       Impact factor: 0.171

Review 2.  Triglyceride-rich lipoproteins and atherosclerosis.

Authors:  P Schwandt
Journal:  Drugs       Date:  1990       Impact factor: 9.546

3.  Low Very low-Density Lipoprotein Cholesterol but High Very low-Density Lipoprotein Receptor mRNA Expression in Peripheral White Blood Cells: An Atherogenic Phenotype for Atherosclerosis in a Community-Based Population.

Authors:  Fan Zhao; Yue Qi; Jing Liu; Wei Wang; Wuxiang Xie; Jiayi Sun; Jun Liu; Yongchen Hao; Miao Wang; Yan Li; Dong Zhao
Journal:  EBioMedicine       Date:  2017-08-31       Impact factor: 8.143

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.